Discover an altogether different kind of CDMO
Partner with creative scientists and problem-solvers dedicated to making your drug development journey a success.
For over 40 years, our experts at Pfizer CenterOne have been listening, solving, and guiding our partners’ drug projects to success.
But what makes us an altogether different kind of CDMO?
A surprisingly refreshing approach to collaboration
Our open and collaborative approach to drug development means we can offer you true transparency across every stage of development as we are on a continuous mission to deliver on what we promise.
A solid foundation to get drug products to market
For over four decades, we have walked in the shoes of drug developers just like you and understand the challenges you face. Learning about your unique needs and ambitions and driving projects like yours on the path to success is what has made us the trusted CDMO partner of choice for customers all over the world.
Draw upon the scientific power of Pfizer
Integrated within a brand name synonymous with success, we strive to bring you the time and dedication of a small-scale CDMO, as well as the resources and expertise of Pfizer.
Manufacturing that scales to any size
By bringing you the capabilities of a global manufacturing network, we can scale with you across every step of your drug manufacturing journey. No goal is too ambitious, and we’re by your side to help you get from where you are now to wherever you want your drug product to be.
A culture of confidentiality where IP remains uncompromised
IP protection is key for any drug development project, which is why we are guided by a culture of confidentiality to ensure your secrets are always safe with us.
Our Environmental, Health and Safety Commitment
Partner with a CDMO that shares your commitment to protecting the environment and our communities around the world. We’re always exploring new ways to minimise our impact on the environment in our mission to develop life-changing medicines for your patients.
Related News
-
Sponsored Content CPHI Online Trend Report: How can flow chemistry help businesses achieve their sustainability goals?
In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
Sponsored Content Discover Our Organic Mineral Salts as APIs
Discover the range of organic mineral salts that serve as Active Pharmaceutical Ingredients available from Dr. Paul Lohmann®. -
Sponsored Content CPHI Podcast Series: Ursatec – celebrating 30 years of pioneering preservative free
In the latest episode of the CPHI Podcast Series, Digital Editor Lucy Chard spoke with Dominik Rocchi of Ursatec. -
Sponsored Content How healthcare trends inform dosage forms
Capsules encompass one of the most popular solid oral dosage forms for pharmaceutical products, with the global empty capsule market predicted to rise to USD $3.7 billion by 2026. The growth in the capsule market can be partly attributed to the many op... -
Sponsored Content Pharma Trend Outlook: Pharma 4.0 and Industry Resilience
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
Sponsored Content CPHI Podcast Series: Key Considerations in Selecting the Right CMO Partner
In this month's episode we hear from Jayna Blake, Senior Project Manager for Technical Programs at Baxter BioPharma Solutions, on key considerations for successful CMO selection. -
Sponsored Content Size doesn’t matter: How smaller deals are shaping healthcare M&A
Several mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With am...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance